Skip to main content
. Author manuscript; available in PMC: 2020 Sep 11.
Published in final edited form as: Nature. 2020 Mar 11;579(7799):415–420. doi: 10.1038/s41586-020-2071-9

Extended Data Figure 6. GSDME overexpression in B16 reduces tumor growth and increases immune responses within tumors.

Extended Data Figure 6.

a, Tumor growth in C57BL/6 mice that were implanted subcutaneously with B16 stably transduced with empty vector (EV) (n=6 mice/group) or to express mGSDME (n=8 mice/group) or inactive F2A GSDME (n=5 mice/group). b, Numbers of CD8+ (left) and NK (middle) TIL and TAM (right) in tumors, normalized to tumor weight. c, Percentage of CD8+ TIL expressing GzmB or PFN (left), and IFN-γ or TNF-α after PMA and ionomycin stimulation (right). d, Percentage of NK expressing Gzm B or PFN. Area under the curve of tumor growth curves in (a) was compared by one-way ANOVA with Holm-Sidak correction for type I error. Comparisons in (b-d) were calculated by one-way ANOVA using the Holm-Sidak method for multiple comparisons. Data are mean + SEM. All data are representative of at least two independent experiments.